Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 13c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($0.93), $0.13 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $600 thousand versus the consensus estimate of $111.11 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Nebius Group closes $5.75B convertible notes offering
• TORM appoints Jann Brown to its board of directors